Research To Practice | Oncology Videos Research To Practice

Featuring perspectives from Dr Julia Foldi, Dr Laura Huppert, Dr Rita Nanda, Dr Saba Shaikh and Dr Sara M Tolaney, including the following topics:
Introduction: Overview of metastatic triple-negative breast cancer (mTNBC) 
Current and emerging strategies for patients with mTNBC (0:00) First-line treatment of mTNBC — Chemotherapy with or without immunotherapy 
Case: A woman in her early 60s with a history of well-controlled HIV is diagnosed with mTNBC — Dr Shaikh (6:10) Case: A woman in her mid 40s with de novo mTNBC — Dr Huppert (20:41) Case: A woman in her late 50s with mTNBC receives up-front pembrolizumab/chemotherapy — Dr Foldi (42:15) Antibody-drug conjugates (ADCs) in the management of mTNBC 
ADCs in the management of mTNBC; sequencing of these agents and ongoing investigations (51:45) Case: A woman in her early 50s with mTNBC receives first-line chemotherapy/immune checkpoint inhibitor followed by sacituzumab govitecan — Dr Shaikh (1:05:32) Case: A woman in her late 30s with mTNBC receives sacituzumab govitecan — Dr Huppert (1:14:21) Case: A woman in her early 40s with mTNBC (IHC 1+) with sacituzumab govitecan-intolerant disease experiences an excellent response to trastuzumab deruxtecan (T-DXd) — Dr Foldi (1:27:30) Case: A woman in her mid 50s with HER2-low metastatic breast cancer receives T-DXd — Dr Shaikh (1:42:00) PARP inhibition for the treatment of mTNBC 
Efficacy and tolerability of olaparib in patients with a germline BRCA mutation and HER2-negative breast cancer  (1:49:49) Case: A woman in her mid 30s with mTNBC receives olaparib — Dr Foldi (1:54:28) Case: A woman in her mid 60s with mTNBC and a BRCA mutation receives olaparib — Dr Huppert (1:59:11) Case: A woman in her mid 40s with a BRCA1 germline mutation and mTNBC receives olaparib — Dr Shaikh (2:03:45) CME information and select publications
 

Featuring perspectives from Dr Matthew D Galsky, including the following topics:
HER2 alterations in urothelial cancer and current targeting approaches (0:00) Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39) Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31) Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57) Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25) Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34) Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48) CME information and select publications

Featuring a slide presentation and related discussion from Dr Sunnie Kim, including the following topics:
Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer — Dr Kim (0:00) Case: A man in his mid 50s with poorly differentiated mismatch repair-deficient advanced gastric cancer receives first-line nivolumab/ipilimumab (49:22) Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who experienced disease progression on FOLFOX/trastuzumab receives trastuzumab deruxtecan (54:48) Case: A man in his mid 60s with Stage IV, PD-L1-positive GEJ adenocarcinoma (58:11) Case: A man in his early 40s with metastatic CLDN18.2-positive gastric/GEJ adenocarcinoma receives zolbetuximab (1:01:10) CME information and select publications

Featuring perspectives from Prof Eric Van Cutsem, including the following topics:
Immune Checkpoint Inhibitors in Localized Gastroesophageal (GE) Cancers 
Introduction (0:00) Case: A man in his mid 50s with localized, poorly differentiated signet ring, mismatch repair-deficient advanced gastric adenocarcinoma — Sunnie Kim, MD (3:39) HER2-Positive GE Cancers
Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma and disease progression on FOLFOX/trastuzumab (PD-L1 CPS 0) — Dr Kim (19:22) First-Line Treatment of Metastatic Gastric and GEJ Adenocarcinoma
Case: A man in his early 40s who presents with metastatic GEJ adenocarcinoma (CLDN18.2-positive, PD-L1 CPS 2) in visceral crisis from lung metastases — Dr Kim (38:53) Case: A man in his mid 60s with metastatic GEJ adenocarcinoma (PD-L1 CPS 20) — Dr Kim (50:50) CME information and select publications

Featuring perspectives from Dr Ruben A Mesa, including the following topics:
Introduction: Journal Club with Dr Mesa (0:00) Case: A woman in her mid 80s with an interesting and unusual presentation of primary myelofibrosis — Bhavana (Tina) Bhatnagar, DO (25:33) Case: A man in his early 70s, asymptomatic, with lower-risk primary MF (JAK2 V617F mutation) — Susannah Friemel, MD (29:42) Case: A woman in her early 80s with pancytopenia and palpable spleen who is diagnosed with primary MF — Jeanne Palmer, MD (35:08) Case: A man in his early 70s with multiple comorbidities and MF (CALR mutation) who receives ruxolitinib 10 mg BID — Ranju Gupta, MD (42:40) ASH 2023 Review (46:13) Faculty Survey (55:41) CME information and select publications

Featuring perspectives from Prof Nicoletta Colombo, Dr Matthew A Powell and Dr Brian M Slomovitz, moderated by Dr Shannon N Westin, including the following topics:
Introduction (0:00) Current Approaches to First-Line Therapy for Advanced Endometrial Cancer (EC) — Prof Colombo (1:57) Novel Investigational Strategies for Newly Diagnosed EC — Dr Westin (25:35) Current Options for Relapsed/Refractory EC — Dr Slomovitz (45:57) Role of HER2-Targeted Therapy in the Management of Advanced EC — Dr Powell (1:05:54) CME information and select publications